선택지 정리됨
충수암 / 복막 가성점액종: 국가별 치료 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨고형암최종 확인 2026.06
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Appendectomy, hemicolectomy, cytoreductive/debulking surgery, systemic chemotherapy, intraperitoneal chemotherapy including EPIC and HIPEC, radiation therapy rarely[1]Standard option (per Memorial Sloan Kettering Cancer Center)Localized appendiceal cancer; carcinoid tumor larger than 2 cm hemicolectomy context; later-stage/spread appendiceal cancer; chemotherapy before/after debulking; rare radiation context if spread to other organs. · This is a single academic-center treatment page, not a national guideline or regulator source. It does not establish that a specific operation, chemotherapy regimen, or radiation approach is appropriate for any individual case. Confidence/conflicts: Medium-high for treatment category mapping; no conflict with NCI, but MSK provides more procedure detail than the NCI rare-tumor overview.
- Surgery to remove appendix and affected abdominal or pelvic organs/tissue; chemotherapy; hyperthermic intraperitoneal chemotherapy (HIPEC)[2]Standard option (per National Cancer Institute)Appendiceal cancer; chemotherapy/HIPEC context when cancer has spread to other parts of the abdomen. · NCI does not provide a stage-by-stage protocol on this page and emphasizes expert evaluation. The page does not establish insurance coverage, center availability, drug choice for HIPEC, or individual surgical suitability. Confidence/conflicts: High for the broad U.S. treatment categories and expert-care caveat; low for regimen-specific details because NCI does not specify them on this page.
United Kingdom
- Watch and wait/active surveillance, cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), debulking surgery, chemotherapy, specialist-centre treatment[3]Standard option (per Cancer Research UK)PMP; slow-growing/small disease monitoring context; CRS/HIPEC where possible; debulking or chemotherapy where appropriate. · CRS/HIPEC is described as major, intensive surgery requiring fitness and resectability assessment. The page does not prove NHS commissioning for an individual patient or specify universal eligibility. Confidence/conflicts: High for UK PMP treatment categories and specialist-centre note; no NICE source was separately fetched in this finding, so NICE details remain link-through rather than independently extracted.
출처
- Memorial Sloan Kettering Cancer Center — academic cancer-center treatment information · academic cancer-center treatment information
- National Cancer Institute — national cancer agency rare-tumor information · national cancer agency rare-tumor information
- Cancer Research UK — UK cancer information / guideline-referenced treatment information · UK cancer information / guideline-referenced treatment information
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026.06.
승인된 치료 너머
임상시험 및 신흥 선택지
환자가 거주하는 국가에서 아직 승인된 표준 치료가 아닌 선택지입니다 — 연구, 임상시험, 허가 외 사용, 담당 종양내과 의사가 먼저 언급하지 않을 수 있는 초기 근거입니다. 각 항목은 근거의 강도에 따라 구분됩니다. 여기에 실린 항목은 조사하고 의료진과 상의할 정보일 뿐, 효과가 입증되었거나 안전하거나 현재 이용 가능하다는 의미가 아닙니다. 임상 세부 내용은 영문이 정본입니다.
임상시험 진행 중
- Low-dose versus high-dose HIPEC with mitomycin C; SGN-STNV; fluorouracil with or without mitomycin C임상시험 · NCT06513065임상시험Trial only (registry)United Kingdom · PMP HIPEC dose comparison; advanced solid tumors including appendiceal adenocarcinoma/PMP; carcinoma of the appendix/peritoneal cancer chemotherapy context. · One study is recruiting, one terminated, and one has unknown overall status with an old last update. The fibrinogen-concentrate PMP surgery study was fetched but skipped as supportive hemostasis rather than direct anticancer treatment. Confidence/conflicts: High for fetched registry support; medium for current availability due to terminated/unknown-status records and absence of HTA/regulator sources. ClinicalTrials.gov — clinical-trial registry
- HIPEC using mitomycin-C with intraoperative blood and peritoneal-fluid sampling임상시험 · NCT05513183임상시험Trial only (registry)Korea · HIPEC using mitomycin-C in peritoneal-metastasis/appendiceal neoplasm/PMP context. · This is a completed safety/toxicity study and does not test antitumor efficacy or establish a treatment recommendation. Confidence/conflicts: High for the Korea-site safety-study record; low for treatment availability beyond the research context. ClinicalTrials.gov — clinical-trial registry
- Surufatinib plus sintilimab plus capecitabine; JAB-21822 plus cetuximab; one versus three HIPEC sessions after cytoreductive surgery; 5-FU exposure/transcriptome study in PMP HIPEC context임상시험 · NCT05472948임상시험Trial only (registry)China · KRAS G12C for JAB-21822 plus cetuximab study; otherwise not specified in the fetched registry text; Metastatic adenocarcinoma of small intestine or appendix carcinoma; advanced appendiceal cancer with KRAS G12C mutation; PMP after cytoreductive surgery/HIPEC; PMP HIPEC regimen evaluation. · Trial statuses vary and one study is non-drug/procedural. Basket studies may include multiple cancers and biomarker restrictions. Registry text does not prove standard-of-care status or access outside the study sites. Confidence/conflicts: High for China-site registry support; no NMPA approval or standard-care claim is made. ClinicalTrials.gov — clinical-trial registry
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC)임상시험 · NCT03210298임상시험Trial only (registry)Russia · Peritoneal malignancy/PIPAC registry including appendix cancer and PMP. · Overall status is unknown despite recruiting site statuses in the fetched location text. The registry includes many tumor types and does not by itself demonstrate appendiceal/PMP-specific outcomes. Confidence/conflicts: Medium-high for listed country sites and condition inclusion; low for current access because overall status is unknown and no regulator source was fetched. trial-registry listing only — does not establish approval, reimbursement, or eligibility ClinicalTrials.gov — clinical-trial registry
임상시험이나 초기 보고에 실렸다는 것은 해당 선택지가 연구되고 있다는 의미일 뿐, 효과가 있거나 특정 환자에게 안전하거나 현재 등록 가능하다는 뜻은 아닙니다. 어떤 선택지가 적합한지는 담당 종양내과 팀과 임상시험 팀이 함께 상의할 문제입니다. 최종 확인 2026.06.
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- Is the disease localized to the appendix or has it spread within the abdomen/peritoneum?
- Is an appendiceal-cancer specialist or peritoneal-surface malignancy program involved?
- Is the discussion about surgery alone, systemic chemotherapy, HIPEC, or a clinical trial?
- What appendiceal tumor type is documented: neuroendocrine/carcinoid, mucinous neoplasm, adenocarcinoma, goblet-cell, or another subtype?